AeroRx Therapeutics
Nebulized combination therapies for COPD
- Sector
- Biotech
- Headquarters
- LA JOLLA, CA
- Founded
- 2024
- Latest Form D
- $10.4M, Oct 2025
- Total capital
- $10.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10.4M
- 1 Form D · last Oct 2025
- 13 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 8 pending · first 2023
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ahmet Tutuncu, M.D., Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Heather Stuart Preston, M.D.DirectorNamed in SEC Form D filings
- Jay B. Lichter, Ph.D.DirectorNamed in SEC Form D filings
- John Stuart Patton, Ph.D.DirectorNamed in SEC Form D filings
- Sanford Madigan, Ph.D.DirectorNamed in SEC Form D filings
- Tighe ReardonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 10- PendingLiquid Formulations Of IndacaterolUSPTOApplication 19315294
- GrantedLiquid Formulations Of IndacaterolUSPTOUS 12,419,883
- PendingLiquid Formulations Of Indacaterol And GlycopyrroniumUSPTOApplication 18852135
Show all 10 patent records
- Liquid Formulations Of IndacaterolMar 19, 2026 · Application 19315294Pending
- Liquid Formulations Of IndacaterolSep 23, 2025 · US 12,419,883Granted
- Liquid Formulations Of Indacaterol And GlycopyrroniumJun 5, 2025 · Application 18852135Pending
- Liquid Formulations Of IndacaterolDec 19, 2023 · US 11,844,793Granted
- Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 63325510Pending
- Liquid Formulations Of IndacaterolApplication PCTUS2021071646Pending
- Liquid Formulations Of Indacaterol And GlycopyrroniumApplication PCTUS2023016847Pending
- Liquid Formulations Of Indacaterol And GlycopyrroniumApplication PCTUS2024022018Pending
- Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 19470557Pending
- Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 63455909Pending
Related companies, and why
- Topo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SG Vector Holdings, LLCSimilar federal contract value in Biotech · null in contracts
- EXCELIMMUNE, INCSimilar federal contract value in Biotech · null in contracts
- Samsara Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MultiValent Biotherapies, Inc.Similar federal contract value in Biotech · null in contracts
- Gallant Pet, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .